Komori
ASKA Pharmaceutical Holdings (4886) · PolicyAdvanced

Reviewing the Rationale for Cross-Shareholdings and Selling Them

First written in FY2022. 5 of 6 entries say "Advanced", first in FY2023. Latest entry: FY2026.

6entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2023 – FY20262022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1268 companies write about · 1 as a headwind · 672 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1272 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「当事業年度において株式数が減少した銘柄 非上場株式以外の株式 4 2,074」

    政策保有株式について、当事業年度に上場株式4銘柄を売却し、売却価額合計2,074百万円となった。
  2. 2026-05-27AdvancedGeneral Meetings of Shareholders

    「As of the end of March 2026, the ratio of the Group’s cross-shareholdings, amounting to ¥11,995 million, to consolidated net assets was 15.62%, down 0.45 percentage points from the end of the previous fiscal year.」

    The company reported a reduction in cross-shareholdings, with their ratio to consolidated net assets declining from the previous fiscal year-end.
  3. FY2025AdvancedAnnual report

    「当事業年度において株式数が減少した銘柄 非上場株式以外の株式 2 125」

    政策保有株式について、当事業年度に上場株式2銘柄を売却し、売却価額合計125百万円となった。
  4. FY2024AdvancedAnnual report

    「当事業年度において株式数が減少した銘柄 非上場株式以外の株式 9 4,230」

    政策保有株式について、当事業年度に上場株式9銘柄を売却し、売却価額合計4,230百万円となったことを記載している。
  5. FY2023AdvancedAnnual report

    「当初の目的や政策保有の意義が薄れたと判断した株式については、取締役会の決議を経て売却することとしております。」

    政策保有株式について、当事業年度に非上場以外の4銘柄を売却し、売却価額合計190百万円を計上している。
  6. FY2022First statedAnnual report

    「We acquire and hold shares to create potential new businesses for the group, establish stable business and collaborative relationships, and maintain and strengthen business alliances in line with our growth strategy. After acquisition, the Board of Directors reviews whether continued ownership is appropriate by examining transactions with the investee company, its financial position and results, share price, dividends and other factors.」

    The company states that cross-shareholdings are held for business creation, transactions and collaboration, and that the Board of Directors reviews whether continued ownership is appropriate.
Moved together

"FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company" moved the same way as this thread, in the same document, in 4 of its 6 moves.

444333★123456
  1. ★This thread
  2. 1FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company4×
  3. 2Development and Launch of a Hair Hormone Measurement Kit4×
  4. 3Launch of the Dysmenorrhea Treatment DroEthi4×
  5. 4Overseas Business Expansion Focused on Asia3×
  6. 5Establishment of an ESG Committee and Identification of 17 Material Issues3×
  7. 6Developing and Utilizing Human Resources Through a New Personnel System and Planned Training3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-27: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.